Treanda
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $6,657 | 6 | 0 |
| 2017 | $10,176 | 21 | 4 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,176 | 21 | 60.5% |
| Unspecified | $6,657 | 6 | 39.5% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) | Teva Pharmaceuticals USA, Inc. | $6,657 | 0 |
Top Doctors Receiving Payments for Treanda
Manufacturing Companies
- Teva Pharmaceuticals USA, Inc. $16,833
Product Information
- Type Drug
- Total Payments $16,833
- Total Doctors 4
- Transactions 27
About Treanda
Treanda is a drug associated with $16,833 in payments to 4 healthcare providers, recorded across 27 transactions in the CMS Open Payments database. The primary manufacturer is Teva Pharmaceuticals USA, Inc..
Payment data is available from 2017 to 2018. In 2018, $6,657 was paid across 6 transactions to 0 doctors.
The most common payment nature for Treanda is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($10,176, 60.5% of total).
Treanda is associated with 1 research study, including "An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)" ($6,657).